Stevanato Group S.p.A. (STVN) Rallies on 2Q26 Revenue Growth and EBITDA Margin Expansion

What happened: Conestoga Capital Advisors' Q3 2026 investor letter highlighted Stevanato Group S.p.A. (NYSE:STVN), noting the company's 2Q26 revenue growth and expanded EBITDA margins. Key numbers: 2Q26 revenue growth of 8%. High-value solutions grew 16% in 2Q. STVN closed at $19.64 on October 27, 2026, with a market capitalization of $5.36 billion. Why it matters: The letter states investor sentiment improved as the company's shift toward higher-value products gained traction, particularly within biologics and GLP-1 therapies, and an improving product mix contributed to margin expansion.

Conestoga Capital Advisors' Q3 2026 investor letter highlighted Stevanato Group S.p.A. (NYSE:STVN), noting the company's 2Q26 revenue growth and expanded EBITDA margins.

The letter states investor sentiment improved as the company's shift toward higher-value products gained traction, particularly within biologics and GLP-1 therapies, and an improving product mix contributed to margin expansion.